Pharma

Cipla June Quarter Profit Jumps 21%

Cipla June Quarter Profit Jumps 21%

Edited by Sandeep Singh | Friday August 07, 2020

Cipla's revenue from the pharmaceuticals segment rose 7.73 per cent to Rs 4,266.09 crore.

Serum Institute To Partner With Gates Foundation To Make COVID-19 Vaccine

Serum Institute To Partner With Gates Foundation To Make COVID-19 Vaccine

Reuters | Friday August 07, 2020

The institute said on Friday it will get funding to support manufacturing for candidate vaccines from AstraZeneca and Novavax.

Zydus Cadila's COVID-19 Vaccine Candidate Found Safe In Early-Stage Human Trial

Zydus Cadila's COVID-19 Vaccine Candidate Found Safe In Early-Stage Human Trial

Reuters | Wednesday August 05, 2020

Zydus plans to complete late-stage trials for ZyCoV-D by February or March and could produce up to 100 million doses a year initially.

Wockhardt To Supply COVID-19 Vaccines To UK

Wockhardt To Supply COVID-19 Vaccines To UK

Reuters | Monday August 03, 2020, Bengaluru

AstraZeneca has indicated it would need 30 million fill-and-finish doses of their vaccine candidate, which the company intends to supply in the next few months, Wockhardt's chairman said.

Sun Pharma Acquires Canada's Aquinox Pharma For $8.2 Million, Shares Gain

Sun Pharma Acquires Canada's Aquinox Pharma For $8.2 Million, Shares Gain

Edited by Sandeep Singh | Wednesday July 29, 2020

Aquinox Pharmaceuticals is a research and development company focused on pharmaceutical products for the purpose of their commercialisation, Sun Pharma said.

Cipla Gets Regulatory Nod To Sell COVID-19 Drug

Cipla Gets Regulatory Nod To Sell COVID-19 Drug

Reuters | Saturday July 25, 2020, Bengaluru

Cipla said it would launch favipiravir as "Ciplenza" in the first week of August, priced at Rs 68 (91 cents) per 200 mg tablet.

Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version

Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version

Reuters | Tuesday July 21, 2020

Glenmark denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.

Biocon Gets Regulatory Nod To Use Drug Itolizumab On COVID-19 Patients

Biocon Gets Regulatory Nod To Use Drug Itolizumab On COVID-19 Patients

Reuters | Sunday July 12, 2020, New Delhi

The drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in the country.

Cipla Set To Undercut Rivals With Generic Remdesivir: Report

Cipla Set To Undercut Rivals With Generic Remdesivir: Report

Reuters | Wednesday July 08, 2020

Sources said the first batch of 10,000 vials had been printed with a price of Rs 4,000, Rs 800 below the cheapest option, launched by European competitor Mylan this week.

Piramal Enterprises Shares Jump After US-Based Carlyle Buys Stake In Pharma Unit

Piramal Enterprises Shares Jump After US-Based Carlyle Buys Stake In Pharma Unit

Edited by Sandeep Singh (with inputs from agencies) | Monday June 29, 2020

Piramal Pharma Share Price: Piramal Enterprises shares rose to as high as Rs 1,387.55 apiece on the BSE during the session.

US-Based Carlyle Buys 20% Stake In Piramal Enterprises' Pharma Business For Rs 3,700 Crore

US-Based Carlyle Buys 20% Stake In Piramal Enterprises' Pharma Business For Rs 3,700 Crore

Edited by Sandeep Singh (with inputs from agencies) | Saturday June 27, 2020

Piramal Pharma will use the capital raised through the dealto accelerate its organic and inorganic growth plans.

Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug

Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug

Edited by Sandeep Singh | Sunday June 21, 2020

Hetero said its generic version of US-based Gilead Science's Remdesivir will be marketed under brand name Covifor in India.

Committee Rejects Former Fortis Promoter Malvinder Singh's Representation On Bail Criteria

Committee Rejects Former Fortis Promoter Malvinder Singh's Representation On Bail Criteria

Press Trust of India | Sunday June 21, 2020, New Delhi

The High Powered Committee said that Malvinder Mohan Singh was at liberty to file a bail application before courts concerned, which shall consider the same on merits in accordance with the law.

Glenmark Gets Approval For Favipiravir As COVID-19 Treatment

Glenmark Gets Approval For Favipiravir As COVID-19 Treatment

Reuters | Friday June 19, 2020

Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014.

Zydus Cadila To Make Gilead's Potential COVID-19 Drug Remdesivir

Zydus Cadila To Make Gilead's Potential COVID-19 Drug Remdesivir

Reuters | Saturday June 13, 2020, Bengaluru

Remdesivir, intravenously administered in hospitals, has already been approved for emergency use in severely-ill patients in the United States, India and South Korea.

12345...6